$NKTR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NEKTAR THERAPEUTICS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NEKTAR THERAPEUTICS. Get notifications about new insider transactions in NEKTAR THERAPEUTICS for free.
Page: < prev 1 2 3 4 5 6 7 ... 12 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 21 2018 | NKTR | NEKTAR THERAPEUTIC ... | WINGER DENNIS L | Director | Sell | S | 59.62 | 15,000 | 894,300 | 42,750 | 57.8 K to 42.8 K (-25.97 %) |
| Aug 21 2018 | NKTR | NEKTAR THERAPEUTIC ... | WINGER DENNIS L | Director | Buy | M | 14.26 | 15,000 | 213,900 | 57,750 | 42.8 K to 57.8 K (+35.09 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | A | 56.90 | 26,250 | 1,493,625 | 26,250 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | A | 56.90 | 26,250 | 1,493,625 | 26,250 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | D | 58.40 | 4,883 | 285,167 | 71,265 | 76.1 K to 71.3 K (-6.41 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | D | 58.40 | 4,883 | 285,167 | 71,265 | 76.1 K to 71.3 K (-6.41 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Grant | A | 0.00 | 10,400 | 0 | 76,148 | 65.7 K to 76.1 K (+15.82 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Grant | A | 0.00 | 10,400 | 0 | 76,148 | 65.7 K to 76.1 K (+15.82 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | D | 58.40 | 8,137 | 475,201 | 180,459 | 188.6 K to 180.5 K (-4.31 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | D | 58.40 | 8,137 | 475,201 | 180,459 | 188.6 K to 180.5 K (-4.31 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Grant | A | 0.00 | 26,000 | 0 | 188,596 | 162.6 K to 188.6 K (+15.99 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Grant | A | 0.00 | 26,000 | 0 | 188,596 | 162.6 K to 188.6 K (+15.99 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | D | 58.40 | 8,207 | 479,289 | 113,059 | 121.3 K to 113.1 K (-6.77 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | D | 58.40 | 8,207 | 479,289 | 113,059 | 121.3 K to 113.1 K (-6.77 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Grant | A | 0.00 | 26,000 | 0 | 121,266 | 95.3 K to 121.3 K (+27.29 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Grant | A | 0.00 | 26,000 | 0 | 121,266 | 95.3 K to 121.3 K (+27.29 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | A | 56.90 | 37,500 | 2,133,750 | 37,500 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | A | 56.90 | 37,500 | 2,133,750 | 37,500 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | D | 58.40 | 5,946 | 347,246 | 85,723 | 91.7 K to 85.7 K (-6.49 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | D | 58.40 | 5,946 | 347,246 | 85,723 | 91.7 K to 85.7 K (-6.49 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Grant | A | 0.00 | 15,000 | 0 | 91,669 | 76.7 K to 91.7 K (+19.56 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Grant | A | 0.00 | 15,000 | 0 | 91,669 | 76.7 K to 91.7 K (+19.56 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | A | 56.90 | 151,250 | 8,606,125 | 151,250 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | A | 56.90 | 151,250 | 8,606,125 | 151,250 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 10.69 | 40,000 | 427,600 | 0 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 10.69 | 40,000 | 427,600 | 0 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | D | 58.40 | 20,389 | 1,190,718 | 264,467 | 284.9 K to 264.5 K (-7.16 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | D | 58.40 | 20,389 | 1,190,718 | 264,467 | 284.9 K to 264.5 K (-7.16 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 0.00 | 60,500 | 0 | 284,856 | 224.4 K to 284.9 K (+26.97 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 0.00 | 60,500 | 0 | 284,856 | 224.4 K to 284.9 K (+26.97 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | D | 60.08 | 40,000 | 2,403,200 | 224,356 | 264.4 K to 224.4 K (-15.13 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | D | 60.08 | 40,000 | 2,403,200 | 224,356 | 264.4 K to 224.4 K (-15.13 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 10.69 | 40,000 | 427,600 | 264,356 | 224.4 K to 264.4 K (+17.83 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 10.69 | 40,000 | 427,600 | 264,356 | 224.4 K to 264.4 K (+17.83 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | D | 58.40 | 6,701 | 391,338 | 83,258 | 90 K to 83.3 K (-7.45 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | D | 58.40 | 6,701 | 391,338 | 83,258 | 90 K to 83.3 K (-7.45 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Grant | A | 0.00 | 26,000 | 0 | 89,959 | 64 K to 90 K (+40.65 %) |
| Aug 16 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Grant | A | 0.00 | 26,000 | 0 | 89,959 | 64 K to 90 K (+40.65 %) |
| Aug 15 2018 | NKTR | NEKTAR THERAPEUTIC ... | WINGER DENNIS L | Director | Sell | S | 60.15 | 17,125 | 1,030,069 | 42,750 | 59.9 K to 42.8 K (-28.60 %) |
| Aug 15 2018 | NKTR | NEKTAR THERAPEUTIC ... | WINGER DENNIS L | Director | Sell | S | 61.04 | 17,125 | 1,045,310 | 59,875 | 77 K to 59.9 K (-22.24 %) |
| Jun 27 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 10.69 | 43,333 | 463,230 | 40,000 | |
| Jun 27 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 10.69 | 43,333 | 463,230 | 83,333 | |
| Jun 27 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 10.69 | 43,334 | 463,240 | 126,666 | |
| Jun 27 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 47.39 | 43,333 | 2,053,551 | 224,356 | 267.7 K to 224.4 K (-16.19 %) |
| Jun 27 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 10.69 | 43,333 | 463,230 | 267,689 | 224.4 K to 267.7 K (+19.31 %) |
| Jun 27 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 49.36 | 43,333 | 2,138,917 | 224,356 | 267.7 K to 224.4 K (-16.19 %) |
| Jun 27 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 10.69 | 43,333 | 463,230 | 267,689 | 224.4 K to 267.7 K (+19.31 %) |
| Jun 27 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 51.82 | 43,334 | 2,245,568 | 224,356 | 267.7 K to 224.4 K (-16.19 %) |
| Jun 27 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 10.69 | 43,334 | 463,240 | 267,690 | 224.4 K to 267.7 K (+19.31 %) |
| Jun 07 2018 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Buy | P | 59.80 | 1,400 | 83,720 | 177,000 | 175.6 K to 177 K (+0.80 %) |
| Jun 07 2018 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Buy | P | 59.07 | 2,000 | 118,140 | 175,600 | 173.6 K to 175.6 K (+1.15 %) |
| Jun 07 2018 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Buy | P | 55.22 | 1,600 | 88,352 | 173,600 | 172 K to 173.6 K (+0.93 %) |
| Jun 07 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 14.26 | 10,000 | 142,600 | 0 | |
| Jun 07 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 55.16 | 10,000 | 551,600 | 274,223 | 284.2 K to 274.2 K (-3.52 %) |
| Jun 07 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Buy | M | 14.26 | 10,000 | 142,600 | 284,223 | 274.2 K to 284.2 K (+3.65 %) |
| Jun 06 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Option Exercise | M | 5.14 | 8,600 | 44,204 | 20,000 | |
| Jun 06 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Option Exercise | M | 5.14 | 1,400 | 7,196 | 28,600 | |
| Jun 06 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Sell | S | 60.00 | 8,600 | 516,000 | 130,333 | 138.9 K to 130.3 K (-6.19 %) |
| Jun 06 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Buy | M | 5.14 | 8,600 | 44,204 | 138,933 | 130.3 K to 138.9 K (+6.60 %) |
| Jun 06 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Sell | S | 61.99 | 1,400 | 86,786 | 130,333 | 131.7 K to 130.3 K (-1.06 %) |
| Jun 06 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Buy | M | 5.14 | 1,400 | 7,196 | 131,733 | 130.3 K to 131.7 K (+1.07 %) |
| May 18 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | S | 83.39 | 3,576 | 298,203 | 65,281 | 68.9 K to 65.3 K (-5.19 %) |
| May 18 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 83.39 | 12,791 | 1,066,641 | 224,356 | 237.1 K to 224.4 K (-5.39 %) |
| May 18 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | S | 83.39 | 4,917 | 410,029 | 162,596 | 167.5 K to 162.6 K (-2.94 %) |
| May 18 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | S | 83.39 | 4,941 | 412,030 | 94,798 | 99.7 K to 94.8 K (-4.95 %) |
| May 18 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | S | 83.39 | 4,060 | 338,563 | 76,201 | 80.3 K to 76.2 K (-5.06 %) |
| May 18 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 83.39 | 3,435 | 286,445 | 63,959 | 67.4 K to 64 K (-5.10 %) |
| May 04 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 5.14 | 15,000 | 77,100 | 0 | |
| May 04 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 14.26 | 10,000 | 142,600 | 10,000 | |
| May 04 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 82.81 | 15,000 | 1,242,150 | 274,223 | 289.2 K to 274.2 K (-5.19 %) |
| May 04 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Buy | M | 5.14 | 15,000 | 77,100 | 289,223 | 274.2 K to 289.2 K (+5.47 %) |
| May 04 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 82.79 | 10,000 | 827,900 | 274,223 | 284.2 K to 274.2 K (-3.52 %) |
| May 04 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Buy | M | 14.26 | 10,000 | 142,600 | 284,223 | 274.2 K to 284.2 K (+3.65 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Option Exercise | M | 10.69 | 30,000 | 320,700 | 0 | |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Option Exercise | M | 10.69 | 30,000 | 320,700 | 30,000 | |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Option Exercise | M | 10.69 | 30,000 | 320,700 | 60,000 | |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | S | 82.86 | 30,000 | 2,485,800 | 99,739 | 129.7 K to 99.7 K (-23.12 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Buy | M | 10.69 | 30,000 | 320,700 | 129,739 | 99.7 K to 129.7 K (+30.08 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | S | 85.63 | 30,000 | 2,568,900 | 99,739 | 129.7 K to 99.7 K (-23.12 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Buy | M | 10.69 | 30,000 | 320,700 | 129,739 | 99.7 K to 129.7 K (+30.08 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | S | 83.65 | 30,000 | 2,509,500 | 99,739 | 129.7 K to 99.7 K (-23.12 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Buy | M | 10.69 | 30,000 | 320,700 | 129,739 | 99.7 K to 129.7 K (+30.08 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 10.69 | 43,333 | 463,230 | 170,000 | |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 10.69 | 43,333 | 463,230 | 213,333 | |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 10.69 | 43,334 | 463,240 | 256,666 | |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 82.86 | 43,333 | 3,590,572 | 237,147 | 280.5 K to 237.1 K (-15.45 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 10.69 | 43,333 | 463,230 | 280,480 | 237.1 K to 280.5 K (+18.27 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 85.63 | 43,333 | 3,710,605 | 237,147 | 280.5 K to 237.1 K (-15.45 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 10.69 | 43,333 | 463,230 | 280,480 | 237.1 K to 280.5 K (+18.27 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 83.65 | 43,334 | 3,624,889 | 237,147 | 280.5 K to 237.1 K (-15.45 %) |
| May 03 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 10.69 | 43,334 | 463,240 | 280,481 | 237.1 K to 280.5 K (+18.27 %) |
| Apr 18 2018 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Option Exercise | M | 14.26 | 30,000 | 427,800 | 0 | |
| Apr 18 2018 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Buy | M | 14.26 | 30,000 | 427,800 | 172,000 | 142 K to 172 K (+21.13 %) |
| Apr 18 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | M | 10.69 | 13,881 | 148,388 | 16,119 | |
| Apr 18 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | S | 101.46 | 13,881 | 1,408,366 | 68,857 | 82.7 K to 68.9 K (-16.78 %) |
| Apr 18 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Buy | M | 10.69 | 13,881 | 148,388 | 82,738 | 68.9 K to 82.7 K (+20.16 %) |
| Apr 12 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | M | 7.21 | 502 | 3,619 | 32,500 | |
| Apr 12 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | S | 105.67 | 502 | 53,046 | 80,261 | 80.8 K to 80.3 K (-0.62 %) |
| Apr 12 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Buy | M | 7.21 | 502 | 3,619 | 80,763 | 80.3 K to 80.8 K (+0.63 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Option Exercise | M | 9.24 | 30,000 | 277,200 | 10,000 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Option Exercise | M | 9.24 | 30,000 | 277,200 | 10,000 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Sell | S | 101.74 | 30,000 | 3,052,200 | 27,450 | 57.5 K to 27.5 K (-52.22 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Sell | S | 101.74 | 30,000 | 3,052,200 | 27,450 | 57.5 K to 27.5 K (-52.22 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Buy | M | 9.24 | 30,000 | 277,200 | 57,450 | 27.5 K to 57.5 K (+109.29 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Buy | M | 9.24 | 30,000 | 277,200 | 57,450 | 27.5 K to 57.5 K (+109.29 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | M | 7.21 | 9,498 | 68,481 | 33,002 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | M | 7.21 | 9,498 | 68,481 | 33,002 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | M | 7.21 | 20,000 | 144,200 | 42,500 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | M | 7.21 | 20,000 | 144,200 | 42,500 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | S | 105.05 | 9,498 | 997,765 | 80,261 | 89.8 K to 80.3 K (-10.58 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | S | 105.05 | 9,498 | 997,765 | 80,261 | 89.8 K to 80.3 K (-10.58 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Buy | M | 7.21 | 9,498 | 68,481 | 89,759 | 80.3 K to 89.8 K (+11.83 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Buy | M | 7.21 | 9,498 | 68,481 | 89,759 | 80.3 K to 89.8 K (+11.83 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | S | 101.75 | 20,000 | 2,035,000 | 80,261 | 100.3 K to 80.3 K (-19.95 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | S | 101.75 | 20,000 | 2,035,000 | 80,261 | 100.3 K to 80.3 K (-19.95 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Buy | M | 7.21 | 20,000 | 144,200 | 100,261 | 80.3 K to 100.3 K (+24.92 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Buy | M | 7.21 | 20,000 | 144,200 | 100,261 | 80.3 K to 100.3 K (+24.92 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Option Exercise | M | 14.26 | 30,000 | 427,800 | 0 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Option Exercise | M | 14.26 | 30,000 | 427,800 | 0 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Sell | S | 92.22 | 30,000 | 2,766,600 | 130,333 | 160.3 K to 130.3 K (-18.71 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Sell | S | 92.22 | 30,000 | 2,766,600 | 130,333 | 160.3 K to 130.3 K (-18.71 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Buy | M | 14.26 | 30,000 | 427,800 | 160,333 | 130.3 K to 160.3 K (+23.02 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Buy | M | 14.26 | 30,000 | 427,800 | 160,333 | 130.3 K to 160.3 K (+23.02 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 7.21 | 49,500 | 356,895 | 0 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 7.21 | 49,500 | 356,895 | 0 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 7.21 | 500 | 3,605 | 49,500 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 7.21 | 500 | 3,605 | 49,500 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 7.21 | 50,000 | 360,500 | 0 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 7.21 | 50,000 | 360,500 | 0 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 10.69 | 60,000 | 641,400 | 0 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 10.69 | 60,000 | 641,400 | 0 | |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 96.13 | 49,500 | 4,758,435 | 67,394 | 116.9 K to 67.4 K (-42.35 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 96.13 | 49,500 | 4,758,435 | 67,394 | 116.9 K to 67.4 K (-42.35 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 7.21 | 49,500 | 356,895 | 116,894 | 67.4 K to 116.9 K (+73.45 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 7.21 | 49,500 | 356,895 | 116,894 | 67.4 K to 116.9 K (+73.45 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 91.69 | 110,500 | 10,131,745 | 67,394 | 177.9 K to 67.4 K (-62.12 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 91.69 | 110,500 | 10,131,745 | 67,394 | 177.9 K to 67.4 K (-62.12 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 7.21 | 500 | 3,605 | 177,894 | 177.4 K to 177.9 K (+0.28 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 7.21 | 500 | 3,605 | 177,894 | 177.4 K to 177.9 K (+0.28 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 7.21 | 50,000 | 360,500 | 177,394 | 127.4 K to 177.4 K (+39.25 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 7.21 | 50,000 | 360,500 | 177,394 | 127.4 K to 177.4 K (+39.25 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 10.69 | 60,000 | 641,400 | 127,394 | 67.4 K to 127.4 K (+89.03 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 10.69 | 60,000 | 641,400 | 127,394 | 67.4 K to 127.4 K (+89.03 %) |
| Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 5.14 | 15,000 | 77,100 | 15,000 |